Journal article
The Landmark Series: Management of Small Bowel Neuroendocrine Tumors
Annals of surgical oncology, Vol.28(5), pp.2741-2751
05/2021
DOI: 10.1245/s10434-020-09566-4
PMCID: PMC8604156
PMID: 33452604
Abstract
Surgical resection is the foundation for treatment of small bowel neuroendocrine tumors (SBNETs). Guidelines for surgical management of SBNETs rely on retrospective data, which suggest that primary tumor resection and cytoreduction improve symptoms, prevent future complications, and lengthen survival. In advanced NETs, improvement in progression-free survival has been reported in large, randomized, controlled trials of various medical treatments, including somatostatin analogues, targeted therapy, and peptide receptor radionuclide therapy. This review discusses important studies influencing the management of SBNETs and the limitations of current evidence regarding surgical interventions for SBNETs.
Details
- Title: Subtitle
- The Landmark Series: Management of Small Bowel Neuroendocrine Tumors
- Creators
- Catherine G Tran - University of IowaScott K Sherman - University of IowaJames R Howe - Roy J. and Lucille A. Carver College of Medicine
- Resource Type
- Journal article
- Publication Details
- Annals of surgical oncology, Vol.28(5), pp.2741-2751
- DOI
- 10.1245/s10434-020-09566-4
- PMID
- 33452604
- PMCID
- PMC8604156
- NLM abbreviation
- Ann Surg Oncol
- ISSN
- 1068-9265
- eISSN
- 1534-4681
- Grant note
- T32 CA078586 / NIH HHS Specialized Programs of Research Excellence Grant / NIH HHS T32 CA078586 / NCI NIH HHS T32 CA148062 / NCI NIH HHS T32 CA148062 / NIH HHS P50 CA174521 / NCI NIH HHS
- Language
- English
- Date published
- 05/2021
- Academic Unit
- Surgery
- Record Identifier
- 9984322809502771
Metrics
15 Record Views